Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans

Dapagliflozin, a selective sodium–glucose co-transporter-2 inhibitor, and linagliptin, a competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed antidiabetic medications in general clinics. Since there are several merits to combining them in a fixed-dose combination product...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jin-Woo, Kim, Jong-Min, Noh, Ji Hyeon, Kim, Kyoung-Ah, Chung, Hyewon, Kim, EunJi, Kang, Minja, Park, Ji-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952231/
https://www.ncbi.nlm.nih.gov/pubmed/35335967
http://dx.doi.org/10.3390/pharmaceutics14030591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952231/
https://www.ncbi.nlm.nih.gov/pubmed/35335967
http://dx.doi.org/10.3390/pharmaceutics14030591

Ejemplares similares